Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
Gastric cancer is a common digestive tract tumor and the second most prevalent cancer. The prognosis of advanced gastric cancer is poor. Conversion therapy can reduce tumor burden, downgrade tumor, and increase the possibility of complete resection, thus prolonging the survival time of patients with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01027/full |
| _version_ | 1818324750376632320 |
|---|---|
| author | Dingyi Jiang Yunyun Xu Yunwang Chen Jiahong Jiang Mingxing Wang Min Yang Zheling Chen Liu Yang |
| author_facet | Dingyi Jiang Yunyun Xu Yunwang Chen Jiahong Jiang Mingxing Wang Min Yang Zheling Chen Liu Yang |
| author_sort | Dingyi Jiang |
| collection | DOAJ |
| description | Gastric cancer is a common digestive tract tumor and the second most prevalent cancer. The prognosis of advanced gastric cancer is poor. Conversion therapy can reduce tumor burden, downgrade tumor, and increase the possibility of complete resection, thus prolonging the survival time of patients with gastric cancer. In conversion therapy, chemotherapy and targeted therapy are the main methods of medical treatment, which can control tumor growth and recurrence. As an antiangiogenic targeted drug, apatinib is widely used in the third-line treatment of advanced gastric cancer. Recent studies have shown that it may be of great help in rapid reduction of tumor stage and improvement of prognosis in conversion therapy. This study reported three cases of gastric cancer complicated with multiple abdominal and retroperitoneal lymph node metastases. After receiving apatinib combined with SOX regimen for four cycles, computed tomography showed that the focus and lymph node metastasis were reduced after treatment, and primary tumors were resected. Postoperative pathology result showed that the patients got R0 resection. After radical surgery, the maintenance therapy including apatinib was given. The progression-free survival time was more than 10 months. Apatinib combined with SOX regimen as a conversion therapy for advanced gastric adenocarcinoma increases the possibility of successful surgical resection, which might prolong the survival time of patients. |
| first_indexed | 2024-12-13T11:33:33Z |
| format | Article |
| id | doaj.art-38434dd397af4c86adf5e06db4f27ec3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-13T11:33:33Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-38434dd397af4c86adf5e06db4f27ec32022-12-21T23:47:52ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-07-011110.3389/fphar.2020.01027565187Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature ReviewDingyi Jiang0Yunyun Xu1Yunwang Chen2Jiahong Jiang3Mingxing Wang4Min Yang5Zheling Chen6Liu Yang7Department of Medical Oncology, The Qingdao University Medical College, Qingdao, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, ChinaDepartment of Medical Oncology, The Qingdao University Medical College, Qingdao, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, ChinaDepartment of Medical Oncology, Bengbu Medical College, Bengbu, ChinaDepartment of Medical Oncology, The Qingdao University Medical College, Qingdao, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, ChinaDepartment of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, ChinaGastric cancer is a common digestive tract tumor and the second most prevalent cancer. The prognosis of advanced gastric cancer is poor. Conversion therapy can reduce tumor burden, downgrade tumor, and increase the possibility of complete resection, thus prolonging the survival time of patients with gastric cancer. In conversion therapy, chemotherapy and targeted therapy are the main methods of medical treatment, which can control tumor growth and recurrence. As an antiangiogenic targeted drug, apatinib is widely used in the third-line treatment of advanced gastric cancer. Recent studies have shown that it may be of great help in rapid reduction of tumor stage and improvement of prognosis in conversion therapy. This study reported three cases of gastric cancer complicated with multiple abdominal and retroperitoneal lymph node metastases. After receiving apatinib combined with SOX regimen for four cycles, computed tomography showed that the focus and lymph node metastasis were reduced after treatment, and primary tumors were resected. Postoperative pathology result showed that the patients got R0 resection. After radical surgery, the maintenance therapy including apatinib was given. The progression-free survival time was more than 10 months. Apatinib combined with SOX regimen as a conversion therapy for advanced gastric adenocarcinoma increases the possibility of successful surgical resection, which might prolong the survival time of patients.https://www.frontiersin.org/article/10.3389/fphar.2020.01027/fullapatinibgastric cancerconversion therapycasereview |
| spellingShingle | Dingyi Jiang Yunyun Xu Yunwang Chen Jiahong Jiang Mingxing Wang Min Yang Zheling Chen Liu Yang Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review Frontiers in Pharmacology apatinib gastric cancer conversion therapy case review |
| title | Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review |
| title_full | Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review |
| title_fullStr | Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review |
| title_full_unstemmed | Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review |
| title_short | Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review |
| title_sort | apatinib combined with sox regimen in conversion treatment of advanced gastric cancer a case series and literature review |
| topic | apatinib gastric cancer conversion therapy case review |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.01027/full |
| work_keys_str_mv | AT dingyijiang apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT yunyunxu apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT yunwangchen apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT jiahongjiang apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT mingxingwang apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT minyang apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT zhelingchen apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview AT liuyang apatinibcombinedwithsoxregimeninconversiontreatmentofadvancedgastriccanceracaseseriesandliteraturereview |